tiprankstipranks
AstraZeneca PLC (CH:ZEG)
:ZEG
Switzerland Market
ZEG
AstraZeneca
RESEARCH TOOLSreports

AstraZeneca (ZEG) Stock Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

ZEG Analyst Ratings

Strong Buy
14Ratings
Strong Buy
12 Buy
1 Hold
1 Sell
Based on 14 analysts giving stock ratings to
AstraZeneca
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ZEG Stock 12 Month Forecast

Average Price Target

CHF172.68
▲(42.04% Upside)
Based on 14 Wall Street analysts offering 12 month price targets for AstraZeneca in the last 3 months. The average price target is CHF172.68 with a high forecast of CHF198.90 and a low forecast of CHF120.84. The average price target represents a 42.04% change from the last price of CHF121.57.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"119":"CHF119","139":"CHF139","159":"CHF159","179":"CHF179","199":"CHF199"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":198.897426,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF198.90</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":172.67800725,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF172.68</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":120.835533,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF120.84</span>\n  </div></div>","useHTML":true}}],"tickPositions":[119,139,159,179,199],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,121.572,127.5201096923077,133.4682193846154,139.4163290769231,145.36443876923076,151.31254846153846,157.26065815384615,163.20876784615385,169.15687753846154,175.1049872307692,181.0530969230769,187.0012066153846,192.9493163076923,{"y":198.897426,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,121.572,125.50323132692309,129.43446265384617,133.36569398076924,137.2969253076923,141.2281566346154,145.15938796153847,149.09061928846154,153.0218506153846,156.9530819423077,160.88431326923077,164.81554459615387,168.74677592307694,{"y":172.67800725,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,121.572,121.5153486923077,121.45869738461539,121.40204607692309,121.34539476923077,121.28874346153846,121.23209215384615,121.17544084615385,121.11878953846154,121.06213823076924,121.00548692307692,120.94883561538461,120.8921843076923,{"y":120.835533,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":121.572,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":121.572,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":121.572,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":121.572,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":121.572,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":121.572,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":121.572,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":121.572,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":121.572,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":121.572,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":121.572,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":121.572,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":121.572,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price TargetCHF198.90Average Price TargetCHF172.68Lowest Price TargetCHF120.84
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Deutsche Bank Analyst forecast on CH:ZEG
Emmanuel Papadakis
Deutsche Bank
Deutsche Bank
CHF122.97
Sell
1.16%
Upside
Reiterated
06/26/26
AstraZeneca (AZN) Gets a Sell from Deutsche Bank
Jefferies Analyst forecast on CH:ZEG
Michael Leuchten
Jefferies
Jefferies
CHF192.49
Buy
58.34%
Upside
Reiterated
06/26/26
AstraZeneca (AZN) Receives a Buy from Jefferies
Morgan Stanley Analyst forecast on CH:ZEG
Sarita Kapila
Morgan Stanley
Morgan Stanley
CHF176.44
Buy
45.14%
Upside
Reiterated
06/24/26
AstraZeneca: SERENA-4 Opportunity Supports Maintained Buy Rating and Unchanged $16,500 Price Target
Citi Analyst forecast on CH:ZEG
Graham Parry
Citi
Citi
CHF192.49
Buy
58.34%
Upside
Reiterated
06/13/26
Citi Initiates a Buy Rating on AstraZeneca (AZN)
Barclays Analyst forecast on CH:ZEG
James Gordon CFA
Barclays
Barclays
CHF176.45
Buy
45.14%
Upside
Reiterated
06/10/26
AstraZeneca (AZN) Receives a Buy from Barclays
J.P. Morgan Analyst forecast on CH:ZEG
Richard Vosser
J.P. Morgan
J.P. Morgan
CHF171.1
Buy
40.74%
Upside
Reiterated
06/09/26
J.P. Morgan Sticks to Their Buy Rating for AstraZeneca (AZN)
Bank of America Securities Analyst forecast on CH:ZEG
Sachin Jain
Bank of America Securities
Bank of America Securities
CHF176.44
Buy
45.14%
Upside
Reiterated
06/09/26
AstraZeneca: Breast Cancer Pipeline Strength Supports Buy Rating as Sachin Jain Reiterates Unchanged 16,500 GBp Price Target
Goldman Sachs Analyst forecast on CH:ZEG
Rajan Sharma
Goldman Sachs
Goldman Sachs
CHF176.71
Buy
45.36%
Upside
Reiterated
06/09/26
Analyst James Quigley Reiterates Buy on AstraZeneca, Citing Undervalued Pipeline‑Driven Growth Upside
Bernstein Analyst forecast on CH:ZEG
Justin Smith
Bernstein
Bernstein
CHF198.9
Buy
63.61%
Upside
Reiterated
06/05/26
Analyst Reaffirms Buy on AstraZeneca, Citing Underappreciated Non‑Oncology Growth and Blockbuster Pipeline Upside
Guggenheim Analyst forecast on CH:ZEG
Seamus Fernandez
Guggenheim
Guggenheim
CHF176.44
Buy
45.14%
Upside
Reiterated
06/03/26
Guggenheim Sticks to Its Buy Rating for AstraZeneca (AZN)
TD Cowen Analyst forecast on CH:ZEG
Steve Scala
TD Cowen
TD Cowen
―
Buy
―
Reiterated
04/30/26
TD Cowen Keeps Their Buy Rating on AstraZeneca (AZN)
UBS Analyst forecast on CH:ZEG
Matthew Weston
UBS
UBS
CHF188.2
Buy
54.81%
Upside
Reiterated
04/30/26
UBS Remains a Buy on AstraZeneca (AZN)
DZ BANK AG Analyst forecast on CH:ZEG
Elmar Kraus
DZ BANK AG
DZ BANK AG
CHF175.37
Buy
44.26%
Upside
Upgraded
04/29/26
Positive Report for AstraZeneca (AZN) from DZ BANK AG
Kepler Capital Analyst forecast on CH:ZEG
David Evans
Kepler Capital
Kepler Capital
CHF120.84
Hold
-0.60%
Downside
Reiterated
04/29/26
Kepler Capital Reaffirms Their Hold Rating on AstraZeneca (AZN)
Berenberg Bank Analyst forecast on CH:ZEG
Luisa Hector
Berenberg Bank
Berenberg Bank
CHF181.8
Buy
49.54%
Upside
Assigned
03/16/26
AstraZeneca (AZN) Gets a Buy from Berenberg Bank
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Deutsche Bank Analyst forecast on CH:ZEG
Emmanuel Papadakis
Deutsche Bank
Deutsche Bank
CHF122.97
Sell
1.16%
Upside
Reiterated
06/26/26
AstraZeneca (AZN) Gets a Sell from Deutsche Bank
Jefferies Analyst forecast on CH:ZEG
Michael Leuchten
Jefferies
Jefferies
CHF192.49
Buy
58.34%
Upside
Reiterated
06/26/26
AstraZeneca (AZN) Receives a Buy from Jefferies
Morgan Stanley Analyst forecast on CH:ZEG
Sarita Kapila
Morgan Stanley
Morgan Stanley
CHF176.44
Buy
45.14%
Upside
Reiterated
06/24/26
AstraZeneca: SERENA-4 Opportunity Supports Maintained Buy Rating and Unchanged $16,500 Price Target
Citi Analyst forecast on CH:ZEG
Graham Parry
Citi
Citi
CHF192.49
Buy
58.34%
Upside
Reiterated
06/13/26
Citi Initiates a Buy Rating on AstraZeneca (AZN)
Barclays Analyst forecast on CH:ZEG
James Gordon CFA
Barclays
Barclays
CHF176.45
Buy
45.14%
Upside
Reiterated
06/10/26
AstraZeneca (AZN) Receives a Buy from Barclays
J.P. Morgan Analyst forecast on CH:ZEG
Richard Vosser
J.P. Morgan
J.P. Morgan
CHF171.1
Buy
40.74%
Upside
Reiterated
06/09/26
J.P. Morgan Sticks to Their Buy Rating for AstraZeneca (AZN)
Bank of America Securities Analyst forecast on CH:ZEG
Sachin Jain
Bank of America Securities
Bank of America Securities
CHF176.44
Buy
45.14%
Upside
Reiterated
06/09/26
AstraZeneca: Breast Cancer Pipeline Strength Supports Buy Rating as Sachin Jain Reiterates Unchanged 16,500 GBp Price Target
Goldman Sachs Analyst forecast on CH:ZEG
Rajan Sharma
Goldman Sachs
Goldman Sachs
CHF176.71
Buy
45.36%
Upside
Reiterated
06/09/26
Analyst James Quigley Reiterates Buy on AstraZeneca, Citing Undervalued Pipeline‑Driven Growth Upside
Bernstein Analyst forecast on CH:ZEG
Justin Smith
Bernstein
Bernstein
CHF198.9
Buy
63.61%
Upside
Reiterated
06/05/26
Analyst Reaffirms Buy on AstraZeneca, Citing Underappreciated Non‑Oncology Growth and Blockbuster Pipeline Upside
Guggenheim Analyst forecast on CH:ZEG
Seamus Fernandez
Guggenheim
Guggenheim
CHF176.44
Buy
45.14%
Upside
Reiterated
06/03/26
Guggenheim Sticks to Its Buy Rating for AstraZeneca (AZN)
TD Cowen Analyst forecast on CH:ZEG
Steve Scala
TD Cowen
TD Cowen
―
Buy
―
Reiterated
04/30/26
TD Cowen Keeps Their Buy Rating on AstraZeneca (AZN)
UBS Analyst forecast on CH:ZEG
Matthew Weston
UBS
UBS
CHF188.2
Buy
54.81%
Upside
Reiterated
04/30/26
UBS Remains a Buy on AstraZeneca (AZN)
DZ BANK AG Analyst forecast on CH:ZEG
Elmar Kraus
DZ BANK AG
DZ BANK AG
CHF175.37
Buy
44.26%
Upside
Upgraded
04/29/26
Positive Report for AstraZeneca (AZN) from DZ BANK AG
Kepler Capital Analyst forecast on CH:ZEG
David Evans
Kepler Capital
Kepler Capital
CHF120.84
Hold
-0.60%
Downside
Reiterated
04/29/26
Kepler Capital Reaffirms Their Hold Rating on AstraZeneca (AZN)
Berenberg Bank Analyst forecast on CH:ZEG
Luisa Hector
Berenberg Bank
Berenberg Bank
CHF181.8
Buy
49.54%
Upside
Assigned
03/16/26
AstraZeneca (AZN) Gets a Buy from Berenberg Bank
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering AstraZeneca

3 Months
Justin SmithBernstein
Success Rate
16/24 ratings generated profit
67%
Average Return
+3.14%
Copying Justin Smith's trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +3.14% per trade.
1 Year
Matthew WestonUBS
Success Rate
35/39 ratings generated profit
90%
Average Return
+16.62%
Copying Matthew Weston's trades and holding each position for 1 Year would result in 89.74% of your transactions generating a profit, with an average return of +16.62% per trade.
2 Years
Matthew WestonUBS
Success Rate
35/39 ratings generated profit
90%
Average Return
+22.82%
Copying Matthew Weston's trades and holding each position for 2 Years would result in 89.74% of your transactions generating a profit, with an average return of +22.82% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ZEG Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
0
0
0
0
0
Buy
29
41
46
45
41
Hold
2
2
3
1
1
Sell
5
7
7
7
7
Strong Sell
0
0
0
0
0
total
36
50
56
53
49
In the current month, ZEG has received 41 Buy Ratings, 1 Hold Ratings, and 7 Sell Ratings. ZEG average Analyst price target in the past 3 months is 172.68.
Each month's total comprises the sum of three months' worth of ratings.

ZEG Financial Forecast

ZEG Earnings Forecast

Next quarter’s earnings estimate for ZEG is CHF1.98 with a range of CHF1.87 to CHF2.11. The previous quarter’s EPS was CHF2.05. ZEG beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ZEG has Performed in-line its overall industry.
Next quarter’s earnings estimate for ZEG is CHF1.98 with a range of CHF1.87 to CHF2.11. The previous quarter’s EPS was CHF2.05. ZEG beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ZEG has Performed in-line its overall industry.

ZEG Sales Forecast

Next quarter’s sales forecast for ZEG is CHF12.29B with a range of CHF11.94B to CHF12.59B. The previous quarter’s sales results were CHF12.09B. ZEG beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ZEG has Performed in-line its overall industry.
Next quarter’s sales forecast for ZEG is CHF12.29B with a range of CHF11.94B to CHF12.59B. The previous quarter’s sales results were CHF12.09B. ZEG beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ZEG has Performed in-line its overall industry.

ZEG Stock Forecast FAQ

What is CH:ZEG’s average 12-month price target, according to analysts?
Based on analyst ratings, AstraZeneca PLC’s 12-month average price target is 172.68.
    What is CH:ZEG’s upside potential, based on the analysts’ average price target?
    AstraZeneca PLC has 42.04% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is AstraZeneca PLC a Buy, Sell or Hold?
          AstraZeneca PLC has a consensus rating of Strong Buy, which is based on 12 buy ratings, 1 hold ratings and 1 sell ratings.
            What is AstraZeneca PLC’s share price target?
            The average share price target for AstraZeneca PLC is 172.68. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is CHF198.90 ,and the lowest forecast is CHF120.84. The average share price target represents 42.04% Increase from the current price of CHF121.57.
              What do analysts say about AstraZeneca PLC?
              AstraZeneca PLC’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.
                How can I buy shares of AstraZeneca PLC?
                To buy shares of CH:ZEG, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.